PMEL and neoplasm: Likewise, several clinical trials have been undertaken in melanoma, employing CAR-T cells directed against various target tumor antigens, including VEGFR2 [56], GD2 in uveal melanoma [57], cMet [58], hCD70 [59], gp100 [60], NY-ESO-1 [61] IL13Ralpha2 [62], B7H3, and Bispecific B7H3xCD19 [63].